Aggressive Treatment in Glioblastoma: What Determines the Survival of Patients?

作者：Yu, Lei^*; Zhang, Guozhong; Qi, Songtao

来源：Journal of Neurological Surgery Part A-Central European Neurosurgery, 2021, 82(02): 112-117.

DOI：10.1055/s-0040-1713172

• glioblastoma
• long-term survival
• IDH1
• 1p
• 19q codeletions
• MGMT
• TERT

Background and Study Aims The exact reason of long-term survival in glioblastoma (GBM) patients has remained uncertain. Molecular parameters in addition to histology to define malignant gliomas are hoped to facilitate clinical, experimental, and epidemiological studies. @@@ Material and Methods A population of GBM patients with similar clinical characteristics (especially similar resectability) was reviewed to compare the molecular variables between poor (overall survival [OS]<18 months, control cohort) and long-term survivors (overall survival>36 months, OS-36 cohort). @@@ Results Long-term GBM survivors were younger. In the OS-36 cohort, the positive rate of isocitrate dehydrogenase (IDH) mutation was very low (7.69%, 3/39) and there was no statistical difference in OS between IDH mutant and wild-type patients. The results of 1p/19q codeletions are similar. Besides, there were no significant difference in MGMT promoter methylation, telomerase reverse transcriptase (TERT) promoter mutation, and TP53 mutations between OS-36 cohort and control cohort. @@@ Conclusions No distinct markers consistently have been identified in long-term survivors of GBM patients, and great importance should be attached to further understand the biological characteristics of the invasive glioma cells because of the nature of diffuse tumor permeation.

• 单位
  南方医科大学